Search | Page 12 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.

    ... are well tolerated in outpatient settings, with azacitidine prolonging survival and decreasing time to acute myeloid ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Myelodysplastic syndromes.

    ... the median survival is 2.5 years. Lenalidomide , azacitidine , and decitabine are all FDA-approved agents to treat ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Decitabine treatment of patients with higher-risk myelodysplastic syndromes.

    ... the relative merits of decitabine compared with azacitidine , the optimal decitabine dose and schedule, how best to proceed ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes.

    ... Among high and very-high IPSS-R patients receiving azacitidine , OS was significantly improved versus patients not receiving azacitidine, with corresponding median OS of 25 versus 18 months (P=0.023) and ...

    Research Article last updated 05/14/2013 - 2:50pm.

  5. Treatment of myelodysplastic syndromes in elderly patients.

    ... Elderly patients with high-risk MDS can benefit from 5- azacitidine (5-AZA), with efficacy and safety profiles comparable with ...

    Research Article last updated 02/10/2012 - 9:43am.

  6. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... anemia , and a chromosome 5 alteration. 5- Azacitidine and decitabine have activity in higher risk MDS. 5-Azacitidine has been shown to improve survival in higher risk MDS. A number of ...

    Research Article last updated 02/04/2014 - 1:37pm.

  7. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... disease, anemia and a chromosome 5 alteration. 5- azacitidine and decitabine have activity in higher risk MDS. 5-azacitidine has been shown to improve survival in higher risk MDS. A number of ...

    Research Article last updated 07/31/2012 - 2:02pm.

  8. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... anemia , and a chromosome 5 alteration. 5- azacitidine and decitabine have activity in higher risk MDS. 5-azacitidine has been shown to improve survival in higher risk MDS. Additional ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Jill Whitney – Since my diagnosis, my mission has been to fight back

    ... was now facing chemotherapy . I began receiving azacitidine (Vidaza®), but my counts were having a hard time recovering. I ... keep me fighting. I recently completed my 34th cycle of azacitidine and have not needed a transfusion in over 2 1/2 years. It has now ...

    Patient Chronicle last updated 05/26/2015 - 9:29am.

  10. Hypomethylating agents for the treatment of myelodysplastic syndromes

    ... August 1, 2011 Azacitidine has been approved in January 2009 in Europe in the treatment of ... in the development of hypomethylating agents 5-azacytidine (azacitidine) and 5-deoxyazacytidine ( decitabine ). Clinical trials of ...

    Research Article last updated 10/11/2011 - 5:58pm.